MET and lung carcinoma: Regarding acquired resistance to osimertinib, several mechanisms including resistance mutations in EGFR (C797S/C796D), MET amplification, and the emergence of other driver oncogenes (KRAS mutations, BRAF mutations, RET fusion, etc.)have been reported in EGFR-mutated lung cancer patients with or without EGFR-T790M mutation6–9.